- Home
- Drug Recall Enforcement Reports
- Recall Enforcement Event ID: 91556
Recall Enforment Report D-0335-2023
Recall Details
Multi event Drug Recall Enforcement Report Class II voluntary initiated by IBSA PHARMA INC, originally initiated on 01-30-2023 for the product TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0110-5 The product was recalled due to subpotent drug. The product was distributed nationwide and the recall is currently terminated.
Recall Enforcement Reports
Recall Number | Recall Initiation Date | Report Date | Recall Classification | Quantity | Product Description | Recall Reason | Status |
---|---|---|---|---|---|---|---|
D-0335-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0110-5 | Subpotent Drug | Terminated |
D-0341-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0125-5 | Subpotent Drug | Terminated |
D-0342-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5 | Subpotent Drug | Terminated |
D-0333-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0140-5 | Subpotent Drug | Terminated |
D-0345-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0160-5 | Subpotent Drug | Terminated |
D-0336-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0112-5 | Subpotent Drug | Terminated |
D-0340-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0120-5 | Subpotent Drug | Terminated |
D-0337-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0113-5 | Subpotent Drug | Terminated |
D-0338-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0115-5 | Subpotent Drug | Terminated |
D-0334-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0155-5 | Subpotent Drug | Terminated |
D-0332-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0130-5 | Subpotent Drug | Terminated |
D-0343-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0145-5 | Subpotent Drug | Terminated |
D-0339-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0117-5 | Subpotent Drug | Terminated |
D-0344-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0150-5 | Subpotent Drug | Terminated |
D-0331-2023 | 01-30-2023 | 03-01-2023 | Class II | N/A | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0105-5 | Subpotent Drug | Terminated |
Recalled Products
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Product Type |
---|---|---|---|---|---|---|
71858-0105 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0110 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0112 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0113 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0115 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0117 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0120 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0125 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0130 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0135 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0140 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0145 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0150 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0155 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
71858-0160 | Tirosint SOL | Levothyroxine Sodium | Solution | Oral | Ibsa Pharma Inc. | Human Prescription Drug |
Recall Enforcement Report D-0335-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0335-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0110-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220856, Exp. 2/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0341-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0341-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0125-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220411, Exp. 10/2023; 220854, Exp. 02/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0342-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0342-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220414, Exp. 10/2023; 220852, Exp. 02/2024; 220970, Exp. 03/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0333-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0333-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0140-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220855, Exp. 2/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0345-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0345-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0160-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220418, Exp. 10/2023; 220560, Exp. 11/2023. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0336-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0336-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0112-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220552, Exp. 11/2023; 221055, Exp. 04/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0340-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0340-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0120-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220853, Exp. 02/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0337-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0337-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0113-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220553, Exp. 11/2023; 221056, Exp. 04/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0338-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0338-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0115-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220407, Exp. 10/2023; 220960, Exp. 03/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0334-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0334-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0155-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220416, Exp. 10/2023; 221053, Exp. 4/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0332-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0332-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0130-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220413, Exp. 10/2023; 220964, Exp. 3/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0343-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0343-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0145-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220415, Exp. 10/2023; 221052, Exp. 04/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0339-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0339-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0117-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220556, Exp. 11/2023; 221058, Exp. 04/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0344-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0344-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0150-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220959, Exp. 3/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recall Enforcement Report D-0331-2023
Field Name | Field Value |
---|---|
Event ID | 91556 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number | D-0331-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification | Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern | Nationwide in the USA. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0105-5 |
Reason For Recall | Subpotent Drug What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity | N/A Product Quantity The amount of product subject to recall. |
Voluntary Mandated | Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date | 03-01-2023 |
Recall Initiation Date | 01-30-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date | 10-31-2023 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification | Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type | Drugs |
Recalling Firm | IBSA PHARMA INC |
Code Info | Lot #: 220409, Exp. 10/2023; 220956, Exp. 03/2024. Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages | 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1 |
Status | Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |